1. Lantheus sold its SPECT business to SHINE Technologies. 2. SPECT divestiture allows Lantheus to focus on PET radiodiagnostics. 3. Lantheus is committed to advancing its pipeline of radiopharmaceuticals. 4. Advisors included Solomon Partners and Foley Hoag LLP. 5. Lantheus aims for better patient outcomes with innovative therapies.
FAQ
Why Bullish?
The strategic divestiture allows Lantheus to concentrate on higher growth PET diagnostics, potentially enhancing market value, similar to how other firms thrived post-divestiture, like GE Healthcare post-spin-off.
How important is it?
The sale signifies a pivotal tactical shift for Lantheus, likely improving financing and resource allocation for innovative products, crucial in enhancing competitive edge.
Why Long Term?
The focus on innovative radiopharmaceuticals may lead to significant business advancements over the next few years, evidenced by previous industry shifts favoring innovation over legacy products.
Lantheus Finalizes Sale of SPECT Business to SHINE Technologies
BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH), a leader in the radiopharmaceutical sector, has announced the completion of its sale of the single photon emission computed tomography (SPECT) business to SHINE Technologies, LLC, a subsidiary of Illuminated Holdings, Inc. This pivotal transaction will allow Lantheus to sharpen its focus on expanding its portfolio of PET radiodiagnostics and advancing its pipeline of innovative radiopharmaceuticals.
Details of the Sale
Under the terms of the agreement, SHINE Technologies has acquired various assets from Lantheus, including:
- Technetium Tc 99m generator (TechneLite®)
- NEUROLITE® (Kit for the Preparation of Technetium Tc 99m Bicisate for Injection)
- Xenon Xe-133 Gas
- Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection)
- The relevant manufacturing site in North Billerica, Massachusetts
- SPECT-related operations in Canada
This divestiture enables Lantheus to prioritize innovative advancements while maintaining its commitment to delivering superior patient outcomes.
Strategic Implications for Lantheus (LNTH)
With the SPECT business now under new ownership, Lantheus is strategically positioned to concentrate on:
- Broadening its commercial portfolio in PET radiodiagnostics
- Advancing its pipeline of radiopharmaceutical innovations
The sale aligns with Lantheus' long-term vision of improving patient care through advanced imaging technologies.
Advisory Support for the Transaction
Lantheus received vital guidance during this sale from various advisory firms:
- Solomon Partners Securities, LLC served as the financial advisor.
- Foley Hoag LLP and Ropes & Gray LLP were engaged as legal advisors.
- Ernst & Young LLP provided financial and tax advisory services.
About Lantheus Holdings (LNTH)
Lantheus is dedicated to assisting clinicians in the detection, treatment, and management of diseases, particularly in the fields of radiopharmaceuticals. By focusing on innovative solutions, the company remains committed to enhancing the quality and outcomes of patient care.